Insider Buying: Pluristem Therapeutics Inc. (NASDAQ:PSTI) Major Shareholder Buys $1,100,991.78 in Stock

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited purchased 121,926 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was bought at an average cost of $9.03 per share, with a total value of $1,100,991.78. Following the acquisition, the insider now owns 3,663,966 shares of the company’s stock, valued at approximately $33,085,612.98. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Monday, July 27th, Clover Wolf Capital – Limited bought 49,396 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $8.34 per share, with a total value of $411,962.64.
  • On Monday, June 29th, Clover Wolf Capital – Limited bought 110,897 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $8.41 per share, with a total value of $932,643.77.
  • On Wednesday, June 24th, Clover Wolf Capital – Limited bought 25,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $8.05 per share, with a total value of $201,250.00.
  • On Monday, June 22nd, Clover Wolf Capital – Limited bought 59,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $7.36 per share, with a total value of $434,240.00.
  • On Thursday, June 18th, Clover Wolf Capital – Limited bought 49,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $7.36 per share, with a total value of $360,640.00.
  • On Wednesday, June 10th, Clover Wolf Capital – Limited bought 25,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $6.91 per share, with a total value of $172,750.00.
  • On Monday, June 8th, Clover Wolf Capital – Limited purchased 178,717 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.36 per share, for a total transaction of $1,315,357.12.
  • On Thursday, June 4th, Clover Wolf Capital – Limited purchased 7,610 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.86 per share, for a total transaction of $59,814.60.
  • On Tuesday, June 2nd, Clover Wolf Capital – Limited purchased 117,489 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.57 per share, for a total transaction of $889,391.73.
  • On Sunday, May 31st, Clover Wolf Capital – Limited purchased 1,797 shares of Pluristem Therapeutics stock. The shares were purchased at an average price of $7.95 per share, for a total transaction of $14,286.15.

PSTI stock opened at $9.80 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.47 and a debt-to-equity ratio of 0.06. Pluristem Therapeutics Inc. has a 12 month low of $2.82 and a 12 month high of $13.29. The firm has a 50-day moving average of $8.46 and a two-hundred day moving average of $6.51.

Several analysts recently commented on the stock. Zacks Investment Research lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. ValuEngine lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Dawson James reiterated a “buy” rating on shares of Pluristem Therapeutics in a research report on Wednesday, April 15th. Jefferies Financial Group lifted their target price on shares of Pluristem Therapeutics from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Finally, Maxim Group reiterated a “buy” rating and issued a $12.00 target price on shares of Pluristem Therapeutics in a research report on Friday, May 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $13.00.

Several institutional investors have recently modified their holdings of PSTI. Renaissance Technologies LLC raised its stake in shares of Pluristem Therapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock valued at $1,077,000 after acquiring an additional 87,188 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Pluristem Therapeutics by 5.9% in the first quarter. Jane Street Group LLC now owns 71,294 shares of the biotechnology company’s stock valued at $262,000 after acquiring an additional 3,945 shares in the last quarter. Focused Wealth Management Inc acquired a new stake in shares of Pluristem Therapeutics in the second quarter valued at $53,000. Evolution Wealth Advisors LLC acquired a new stake in shares of Pluristem Therapeutics in the second quarter valued at $27,000. Finally, ETF Managers Group LLC raised its stake in shares of Pluristem Therapeutics by 9.8% in the first quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 5,764 shares in the last quarter. Institutional investors and hedge funds own 7.82% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Further Reading: Are all No-Load Funds Equal?

Insider Buying and Selling by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.